Author

Briana Noble

Ionis Pharmaceuticals (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Organism:human· 1 Assay:proteomics· 1 Organism:rat· 1 Approach:statistical model· 1

Frequent Co-Authors

Hien Tran ZhaoiD· 3 shared Holly B. KordasiewicziD· 2 shared Abdul Basit Shaikh· 1 shared Aliza Ben-Varon· 1 shared Alyssa SeerleyiD· 1 shared Andrea Compton· 1 shared Andrea Grindeland Panter· 1 shared Andrew G. ReidenbachiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersNeuroscience

Hien Tran ZhaoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

PrP turnover in vivo and the time to effect of prion disease therapeutics

Taylor L Corridon, Jill O’Moore, Alyssa Seerley, Daniel A. Sprague, Yuan Lian, Vanessa Laversenne, Briana Noble, Nikita G Kamath, Fiona E. Serack, Abdul Basit Shaikh, Brian Erickson, Craig R. Braun, Kendrick DeSouza-Lenz, Michael Howard, Nathan Chan, , Eric Vallabh Minikel

The paper measures PrP half-life in vivo and shows it limits the time to effect of PrP-lowering therapies, with implications for drug development and clinical trial design.

PLoS Pathogens · May 26, 2026Peer-reviewedNeuroscience

Atrophin-1 Antisense Oligonucleotide Provides Robust Protection from Pathology in a Fully Humanized DRPLA Model

Velvet L. Smith, Bereket Z. Gidi, Robert M. Bragg, Jeffrey P. Cantle, Aliza Ben-Varon, Briana Noble, Sílvia Prades, Andrea Compton, Julie Greenfield, Joanna A. Korecka, Anya Gemos, Timothy W. Yu, Vikram Khurana, Holly B. Kordasiewicz, Hien Tran Zhao, , Jeffrey B. Carroll

This paper demonstrates that antisense oligonucleotides targeting human ATN1 protect against DRPLA pathology in a fully humanized mouse model.

Molecular Therapy — Nucleic Acids · Dec 31, 2025Peer-reviewedNeuroscience

Analgesic actions of Intrathecal NaV 1.7 antisense in rats: loss of antagonist channel binding, message depletion, and neuraxial distribution of oligonucleotide

Kauê Franco Malange, Júlia Borges Paes Lemes, Briana Noble, Yuvicza Anchondo, Carlos Eduardo Morado-Urbina, Saee Jadhav, Sara Anna Dochnal, Chiraag Kambalimath, Pedro Álvarez, Bethany Fitzsimmons, Curt Mazur, Holly B. Kordasiewicz, Kim Doré, Hien Tran Zhao, Tony L. Yaksh

This study evaluates the analgesic effects of intrathecal NaV 1.7 antisense oligonucleotides in rats, showing reduced channel binding and pain behaviors with concentration-dependent knock-down of Scn9a mRNA.

bioRxiv · May 19, 2025 · PreprintNeuroscience